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PrediCtors of Positive deCision outComes by the CAnCer drugs fund
Smith NJ1, Beckerman R2
1CBPartners, New York, NY, USA, 2Maple Health Group, LLC, New York, NY, USA
Objectives: To build a predictive model of acceptance of drugs to the United 
Kingdom’s (UK) Cancer Drugs Fund (CDF) based on the scores for each factor 
published in the public decision summaries. MethOds: All decision summaries 
published from December 2014 until May 2015 were included. For each decision 
summary, data were collected regarding the drug indication, scores for each decision 
factor (progression-free survival: PFS, overall survival: OS, quality-of-life: QoL, and 
unmet need), total clinical score, strength of evidence, cost, and decision outcome. 
Decisions to either retain or place drugs on formulary were counted as positive 
decisions; all other decisions were classified as negative decisions. A generalised 
linear model (GLM) was used to estimate the odds of each factor resulting in a 
positive decision; univariate and multivariate analyses were performed. Results: 
62 decisions were issued in the study period for a total of 34 different drugs; 2 
drugs were not formally assessed due to a lack of comparison against the standard 
of care in the UK. Only 22 of 64 (34.4%) of drugs received positive decisions from 
the CDF since December 2014, with an average total clinical score of 2.85. Median 
PFS and OS scores were 2 and 0, respectively, indicating most drugs did not have 
significantly improved OS as assessed by the CDF. Univariate results from the GLM 
demonstrated that PFS and OS gains resulted in higher odds of approval with odds 
ratios of 1.56 (95%CI:1.15-2.22) and 1.63 (95%CI:1.11-2.71), respectively. A multivariate 
analysis also demonstrated significant effects of PFS (OR:2.12,95%CI:1.43-3.50), OS 
(OR:2.35,95%CI:1.19-6.97), and a trend for QoL (OR:2.58,95%CI:0.73-9.93). Monthly 
cost was not a significant predictor of outcome in the model. cOnclusiOns: The 
majority of decisions since the 2015-2016 CDF procedures update have been nega-
tive; greater gains in PFS and OS significantly improved the likelihood of a positive 
CDF review outcome.
mediCAl deviCe & diAgnostiC reseArCh studies
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Objectives: Since 2011, the number of health technology assessments (HTAs) on 
pharmacological therapies increases annually. As countries worldwide are trying 
to curb overall healthcare expenditure, the objective of this study was to analyse 
if this upward trend is also found in the area of medical devices. MethOds: One 
hundred HTA agencies were selected. Their reports on medical devices since 2011 
were analyzed by number and type and matched with HTAs for pharmacological 
therapies. Results: Not all of the included agencies assess medical devices. Most 
device HTAs are carried out in the UK, France, Sweden, the US and Australia, match-
ing their overall high HTA activity. However, other countries with high drug HTA 
activity (Germany, Spain, the Netherlands) focus less on devices. Most device-related 
HTAs are indicated for cardiovascular diseases, while pharmaceuticals are domi-
nated by oncology. The number of HTAs on pharmacological therapies increases 
every year (with seasonality), while the number of device HTAs remained steady over 
the last 5 years. Generally, HTA agencies seem to perform device evaluations more 
on an ad-hoc basis. cOnclusiOns: Although the total number of HTAs performed 
worldwide is increasing, the number of device assessments remained fairly stable. 
However, manufacturers seem to realize HTA importance and need to adapt to EU 
regulations. The increased clinical requirements in the draft EU Medical Devices 
Regulation will enable manufacturers to find their role in this growing area.
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Objectives: The rise in molecular diagnostic testing in oncology has made these 
tests the subject of an increasing number of investment discussions, reimbursement 
negotiations and hospital cost calculations. This requires a detailed assessment 
of the total cost for determining tumor mutation status beyond plain kit costs. 
This research maps the workflow, identifies investment needs and quantifies the 
direct variable costs of KRAS and NRASmutation testing from formalin fixed paraf-
fin embedded (FFPE) sample to result. MethOds: The complete test workflow is 
based on the current workflow in two academic European institutions. Hands-on 
time and consumables used in each step were quantified in both hospitals. Unit 
cost was obtained from the finance departments. Results: Costs related to tumor 
mutation tests include investments (lab space, lab equipment, molecular diagnostic 
systems, training, quality assurance, accreditation), indirect costs, lab running costs 
(disinfection, cost of errors and repeats) and direct variable costs including reagent 
costs, controls and labor. The total cost depends on workflow and tumor profile. To 
detect a wild-type RAS tumor, the direct variable costs from FFPE sample to result 
excluding reagent costs, is estimated at € 64 using a CE-IVD kit for KRAS exon 2 
followed by pyrosequencing for NRAS exon 2 and extended RAS testing, € 51 using 
High Resolution Melting confirmed by pyrosequencing and € 3 for an automated 
instrument. The latter automated technology includes sample preparation in the 
test cost, as it works directly from FFPE. cOnclusiOns: Estimations on the cost 
of performing tumor mutation tests should include not only reagent costs, which 
are usually considered, but also investments, lab running costs, labor and all other 
direct and indirect costs. Even in the most advanced labs, efforts are needed to fully 
and subsequent clinical outcomes in chemotherapy-naïve mCRPC. MethOds: 
COU-AA-302 was a multinational, double-blind, randomized phase 3 trial of abira-
terone acetate plus prednisone compared with prednisone alone in asymptomatic 
or mildly symptomatic mCRPC patients without previous chemotherapy. Using 
data from the entire COU-AA-302 patient population (N = 1088) over the first 181 
days of treatment, we explored the relationships between clinical time-to-event 
end points and changes in PROs measuring pain, physical well-being (PWB), func-
tional well-being (FWB), and prostate cancer–specific signs and symptoms. Cox 
regression models were developed to assess the relationship between each PRO 
(separately and for all 4 simultaneously), and radiographic progression-free survival 
(rPFS) as the dependent variable, adjusting for important baseline clinical and PRO 
characteristics. Results: In each individual model, patients with worsening PROs 
were at greater risk of radiographic progression compared with patients whose 
PRO scores improved or remained stable during the follow-up period. Hazard ratios 
(95% confidence intervals) for worsening pain intensity, PWB, FWB, and prostate 
cancer–specific symptoms were 1.68 (1.28-2.21), 2.08 (1.60-2.71), 1.35 (1.04-1.74), and 
1.52 (1.18-1.95), respectively (all p ≤ 0.02). When all 4 PRO end points were included 
in a single multivariate model, a worsening in PWB was the most significant factor 
associated with worse rPFS. There were too few events at the time of analysis cut-
off to explore the relationship between survival and PROs. cOnclusiOns: These 
results demonstrate a significant temporal relationship between PROs and disease 
progression. Worsening of PROs was associated with an increased likelihood of 
radiographic progression. In addition to their traditional utility in describing patient-
relevant outcomes in clinical trials, PROs may be valuable clinical monitoring tools 
when following patients for disease progression.
CA2
the esmo mAgnitude of CliniCAl benefit sCAle for novel CAnCer 
mediCines — CorresPondenCe With PrioritizAtion deCisions in 
uPdAting the isrAeli nAtionAl list of heAlth serviCes
Hammerman A1, Greenberg-Dotan S1, Feldhamer I1, Birnbaum Y1, Cherny NI2
1Clalit Health Services, Tel-Aviv, Israel, 2Shaare-Zedek Medical Center, Jerusalem, Israel
Objectives: The Israeli National Health Insurance Law stipulates a National List 
of Health Services (NLHS) which all residents are entitled to. Every year, the govern-
ment determines the additional budget to be allocated for new health technologies 
on the NLHS. A public national advisory committee (PNAC) evaluates and prioritizes 
all proposed technologies. The PNAC takes into account mainly the efficacy of the 
new technology, but also economic, social and ethical aspects. However, until now, 
no standard tool was available for grading the extent of benefit of therapies. The 
European Society for Medical Oncology (ESMO) published recently its Magnitude 
of Clinical Benefit Scale (ESMO-MCBS) for cancer medicines. The scale is graded 5, 
4, 3, 2, 1, for treatments of advanced/metastatic cancers (the ‘palliative setting’), 
where grades 5 and 4 represent the highest level of proven clinical benefit. Our 
objective was to examine, in retrospect, whether the novel cancer drugs that were 
recommended for reimbursement by the PNAC, had higher ESMO-MCBS scores 
than the candidate drugs that were not approved in the 2015 NLHS update pro-
cess. MethOds: ESMO-MCBS scores were obtained for the cancer drugs that were 
candidates for the 2015 NLHS update. Fisher’s Exact Test was used to compare scores 
of drugs approved and those not approved for reimbursement. Results: 17 cancer 
drugs were candidates for the 2015 NLHS update deliberations. An ESMO-MCBS 
score was available for 5/7 approved drugs and 8/10 non-approved drugs. 80% of the 
approved drugs and none of the non-approved drugs gained a score> = 3 (p= 0.007). 
Median scores were 3 and 1 respectively. cOnclusiOns: The Israeli PNAC’s deci-
sions regarding reimbursement for novel cancer drugs seem to be in concordance 
with ESMO-MCBS scores. The structured and consistent approach of the ESMO-
MCBS could further assist in framing the appropriate use of limited public resources 
to deliver effective and affordable cancer care.
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Objectives: When people die due to cancer, their contribution to society through 
paid work, called production, is lost. Previous estimates of cancer-related lost 
production have focussed on developed countries. However, developing nations 
account for approximately 70% of the world’s annual cancer deaths. We estimate 
the value of lost productivity due to cancer mortality in the rapidly emerging econo-
mies of Brazil, Russia, India, China and South Africa (BRICS) and compare it to 
the UK. MethOds: Based on the Human Capital Approach, we valued the lost 
productivity associated with premature cancer deaths in BRICS countries and the 
UK in 2012. We used GLOBOCAN estimates of cancer deaths by country, sex and 
age group, along with OECD and national data for workforce participation, unem-
ployment, and wage rates. Sensitivity analyses examined the impact of changing 
assumptions about wages, life expectancy and discounting. Results: The total 
cost of cancer-related lost productivity in the UK in 2012 was € 3 billion, and in 
the BRICS countries combined was over € 24 billion. Losses were highest in China 
(€ 12.9 billion) and lowest in South Africa (€ 0.9 billion). When adjusted by number of 
deaths, lost productivity (per death) were highest in South Africa (€ 19,000), the UK 
(€ 19,000), and Brazil (€ 14,000) and lowest in India (€ 3,000). There were large differ-
ences between countries in terms of lost productivity when examined by gender, age 
and cancer. For example, the cancers contributing highest productivity losses were 
lung cancer in Russia (22% of total), South Africa (14%), Brazil (13%) and the UK (11%), 
stomach cancer in India (11%), and liver cancer in China (31%). cOnclusiOns: 
In many developing countries cancer now kills more people than AIDS, malaria 
and tuberculosis combined, however resources have not shifted correspondingly. 
Valuing cancer-related lost productivity provides policy-makers with an additional 
perspective on priorities for cancer prevention and control.
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treatment line. Association between the annual treatment cost per patient and 
the attributes was studied using Pearson correlation coefficient (for quantitative 
variables), ANOVA (for qualitative variables), and generalized linear model using 
gamma distribution. Results: Annual treatment costs varied from 1,500€ to almost 
1,000,000€ . Bivariate analysis showed a significant association between the annual 
treatment cost and disease prevalence, age group, treatment line, alternative treat-
ments, therapeutic area, and ATC class (p< 0.05 for all). Significantly higher cost was 
observed in pediatric population, first treatment line, metabolic diseases, or in case 
of absence of alternative treatment. Multivariate analysis including these variables 
did not showed significant results. Given the complex correlation structure between 
the co-variates, the model including only the prevalence and alternative treatments 
was tested. Both co-variates were significant. cOnclusiOns: Disease prevalence 
and unmet needs seems to be the main drivers of ODs prices while the level of 
clinical evidence and disease severity had no impact. However, this is difficult to 
justify statistically because of high variance and small number of observations. 
Interestingly, ASMR score presented by the HAS as main price driver was not shown 
having an impact on drug prices.
Pr2
PrediCting Post-Amnog rebAte outComes for onCology drugs
Subramanian D, Lazaro V
Qlaar Pte. Ltd., Singapore, Singapore
Objectives: New drugs launching into Germany undergo benefit assessment 
by G-BA, followed by a price negotiation with GKV-Spitzenverband (GKV-SV). In 
this paper we analyze the determinants of German rebate outcomes for oncol-
ogy drugs. MethOds: We used the (Coveragedecisions} payer decision database 
as the basis of this analysis. This database consists of systematically abstracted 
data from publicly available payer decisions on pricing, reimbursement, HTA 
and formulary coverage decisions from 21 countries worldwide, covering all new 
molecular entities (NMEs) approved in EU or US since 2011. We extracted data from 
the (Coveragedecisions} payer decision database on G-BA benefit assessment and 
GKV-SV pricing outcomes of all oncology NMEs with a known GKV-SV pricing out-
come. The data extracted included G-BA benefit rating at subgroup level, relative 
sizes of subgroups, intervention and comparator costs by subgroups, time limi-
tations on benefit determination and magnitude of rebate. We then conducted a 
stepwise multiple linear regression with backward elimination, with magnitude 
of post-AMNOG rebate as the dependent variable, and benefit category, difference 
between intervention and comparator costs and presence of time limit on benefit 
recommendation as the independent variables. Results: Of the 27 benefit assess-
ments analyzed, rebates varied from 10%-54%. The final model (adjusted R square 
0.75; F statistic 9.35; p< 0.001) showed that the difference between intervention 
and comparator costs was a significant predictor of rebate (p= 0.004). Compared to 
‘indication of considerable benefit’, ‘no benefit’ (p= 0.001) and ‘hint of minor benefit’ 
(p< 0.001) were associated with significantly higher rebates. Though other benefit 
ratings did not achieve statistical significance, directionally, ‘proof of minor benefit’ 
and ‘indication of lower benefit’ were associated with higher rebates compared to 
‘indication of considerable benefit’. cOnclusiOns: Based on our analysis, GKV 
rebate for oncology drugs can be expressed using a multiple regression equation, 
as a function of G-BA benefit rating category and incremental cost vs. comparator.
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Maljanen T1, Martikainen JE1, Koskinen H1, Vogler S2
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Objectives: The growing costs of medicines have forced many countries to imple-
ment measures to lower the prices of originators and generics after patent expira-
tion. Measures taken in Austria include Generic Price Linkage System, where there 
are strict upper limits for the prices of generics and also for originators after the 
entry of generics. Measures taken in Finland include Generic Substitution and 
Reference Pricing, where competition plays an important role. The aim of this 
study is to compare the effects of the measures taken in Austria and in Finland on 
the prices of originators and generics. MethOds: We included in the analysis ten 
active ingredients whose sales were high in Finland, which were reimbursable in 
both countries, and whose patent protection expired during the years 2010–2012. 
The analysis was based on time series, which covered 6 months before and 12 
months after the entry of the first generic. The changes in price levels were meas-
ured in terms of wholesale prices proportioned to the number of Defined Daily 
Doses in the package (EUR/DDD). Results: One year after generic entry, prices 
for originators had fallen, on average, by 46% in Austria and by 21% in Finland. 
Prices for generics were 66% lower in Austria and 59% lower in Finland than the 
prices of originators before generic entry. The mean number of generics per active 
ingredient was 6.3 in Austria and 5.1 in Finland. cOnclusiOns: The pricing sys-
tem applied in Austria appears to be more efficient in lowering prices than the 
system used in Finland, which contradicts claims that free competition lowers 
generic prices more efficiently than linking them to the price of the originator. 
This finding may be due to the way the Finnish Reference Price System has been 
constructed.
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Objectives: Recent advances in treating Hepatitis C (HCV) have prompted sig-
nificant debate about affordability. The objective of this research was to investi-
gate Health Technology Assessment (HTA) agencies’ approach to assessment and 
the impact of evidence criteria on recommendations. MethOds: HTA reports 
published on HCV since 2014 were reviewed. The four most frequently assessed 
drugs were further scrutinized in terms of clinical benefit, costs and recommen-
understand the total cost of ownership as this will become ever more important for 
future market access, reimbursement and financial discussions.
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Objectives: Given the high burden of cardiovascular diseases treated in primary 
prevention with the implantable cardioverter defibrillator (ICD), the monitor of 
healthcare expenditure related to such diseases is essential for health policy mak-
ers. This study assessed the variation in costs of patients with ICD over time, from 
3 years before the first implant up to 8 years after. MethOds: Patients covered 
by Lombardy Healthcare System (HS) who underwent an ICD implantation in the 
period 2003-2010 were identified through regional healthcare administrative data-
bases (HAD). Data extracted from these HAD were linked with clinical information 
collected in the national ICD registry, and for each patient we selected the first 
implant performed in primary prevention. We identified drug prescriptions, hospi-
talizations and outpatient visits provided to patients for their cardiovascular disease 
during the 3 years before and the 8 years after the implant. For the same period, we 
estimated the trend in mean annual per capita cost through the Bang and Tsiatis 
method, that considers censoring in cost data. Results: Patients with a first ICD 
implanted in primary prevention were 6,936 (82% males, mean age 65 years) and 
we observed a yearly mortality rate of 6.9% (95% Confidence Interval (CI): 6.6-7.3) 
during follow-up. During the 3 years before the implant, the mean annual per capita 
cost was € 3,424 (95%CI: 3,331-3,537) and it increased to € 4,136 (95%CI: 4,004-4,262) 
after ICD implantation. However, before the ICD implantation we observed a grow-
ing trend in mean annual per capita costs, while after the intervention this trend 
was negative. cOnclusiOns: Our study confirmed the high economic impact of 
cardiovascular diseases on the HS when treating subjects with left ventricular sys-
tolic dysfunctions or heart failure. Different trends in the healthcare expenditure 
were detected pre and post ICD implantation, but the significance of such difference 
should be further explored.
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Objectives: 18F-FDG-PET/CT is accurate in detecting distant metastases (DM) 
in breast cancer patients scheduled for neoadjuvant chemotherapy. If DMs are 
screen-detected in an early phase, morbidity and mortality may be reduced. 
Because 18F-FDG-PET/CT comes at a significant cost, we compared its expected 
cost-effectiveness in stage II/III breast cancer patients of the UK, the US and the 
Netherlands (NL) vs. the gold-standard (X-thorax/liver sonography/bone scan (UK/
NL) and CT-thorax-abdomen/bone scan (US)). MethOds: A time-dependent Markov 
model compared expected Life Year (LY) and cost/Quality-adjusted Life Year (QALY) 
gained in four breast cancer subtypes (ER-/HER2+;ER+/HER2+;ER-/HER2-;ER+/HER2-) 
over a 5-year time horizon from a hospital perspective. Sensitivity and specific-
ity of imaging and type of systemic and local treatments were derived from the 
Netherlands Cancer Institute. Epidemiological, survival and utility data were esti-
mated from literature or informed by expert assumptions. Costs (2013) were derived 
from national tariffs (UK and NL), and from the Centres for Medicaid and Medicare 
Services (US). Results: 18F-FDG-PET/CT is more sensitive (53% vs. 15%) and specific 
(97% vs. 94%) than the gold-standard. LYs and QALYs gained were similar across 
subtypes, ranging from 0.025 to 0.027 and 0.0037 to 0.0044 respectively. In all coun-
tries, ER+HER2+ was the least and ER+HER2- the most costly group. 18F-FDG-PET/
CT is expected to be cost-effective in the NL and the US (with highest ICERs of € 165/
QALY in ER+/HER2+ and $750 in ER-HER2+), with probabilities of cost-effectiveness 
ranging from 46-52% and 62-72% respectively, but not in the UK, with a 66-75% prob-
ability, depending on tumor subtype. cOnclusiOns: Using 18F-FDG-PET/CT for DM 
screening in stage II/III breast cancer is expected to result in incremental QALY gains 
in all subtypes and countries. Due to costs differences between countries, 18F-FDG-
PET/CT is expected to be cost-effective in the US and the NL, but not in the UK.
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Objectives: No specific market access process has been developed for orphan 
drugs (ODs) in France, but there is an unspoken will to support these medicines. 
Pricing process of ODs is unclear, and many of them became blockbusters despite 
the small size of the targeted population. The aim of the study is to identify the 
main drivers of ODs prices in France. MethOds: ODs prices were extracted from 
Ameli database. Drugs and diseases attributes were defined based on the reports 
of the European Medicines Agency and Haut Authorité de Santé (HAS). Attributes 
included the prevalence, ATC class, therapeutic area, disease severity, alternative 
treatments, level of clinical evidence, SMR and ASMR scores, year assessment, and 
